A “mix‐and‐use” approach for formulation of human clinical doses of <sup>177</sup><scp>Lu‐DOTMP</scp> at hospital radiopharmacy for management of pain arising from skeletal metastases
Sudipta Chakraborty, Ashutosh Dash(Bhabha Atomic Research Centre), E. R. Radhakrishnan(Kovai Medical Center and Hospital), Ajit Shinto(Kovai Medical Center and Hospital), A. Rajeswari(Bhabha Atomic Research Centre), Koramadai Karuppusamy Kamaleshwaran(Kovai Medical Center and Hospital), Rubel Chakravarty(Bhabha Atomic Research Centre), K.V. Vimalnath(Bhabha Atomic Research Centre), Haladhar Dev Sarma(Bhabha Atomic Research Centre)
Cited by 7
Related Papers
Production of 177Lu for Targeted Radionuclide Therapy: Available Options
|Nuclear Medicine and Molecular Imaging|2015|375
Sustained Availability of <sup>99m</sup>Tc: Possible Paths Forward
|Journal of Nuclear Medicine|2012|140
Peptide Receptor Radionuclide Therapy: An Overview
|Cancer Biotherapy and Radiopharmaceuticals|2015|122
Targeted Radionuclide Therapy - An Overview
|Current Radiopharmaceuticals|2013|117
Development of an electrochemical 90Sr–90Y generator for separation of 90Y suitable for targeted therapy
|Nuclear Medicine and Biology|2008|99